Business Wire

NJ-PMC-GROUP

Share
PMC Group and The Chakrabarti Foundation Make Donation to Ramakrishna Mission Saradapitha Belur Math of West Bengal

Paritosh M. Chakrabarti, business owner, author and philanthropist, today announced PMC Group and The Chakrabarti Foundation have made a sizeable donation of land and property to the Ramakrishna Mission Saradapitha Belur Math of West Bengal.

“Contributing to the Ramakrishna Mission Saradapitha is an honor. The Mission enshrines the teachings of India’s greatest spiritual leader and unifier of humanity, Swami Vivekananda,” explained Paritosh Chakrabarti. “This gift is a way for me to further those ideals. I am appreciative to Belur Math for accepting the donation. These gifts are also part of the ‘soul’ of PMC Group that I describe in my upcoming book, The Makings of PMC Group – A Corporation with a Soul."

The donation includes the notable Bose House which has been witness to many historical events and carries memories of great patriots and revolutionaries, the surrounding land, and a significant financial gift. The financial gift will provide for 1.) construction and development of two museum rooms, each housing panel exhibition-cum-photo galleries, manuscripts, rare and valuable collections and potentially, a multimedia presentation depicting the lives, activities, and legacies of Swami Vivekananda and Netaji Subhas Chandra Bose, 2.) production of cultural and educational activities to promote inter-cultural and inter-religious harmony and, 3.) installation of a commemorative plaque stating: “This historic Bose House Property has been donated by Paritosh M. Chakrabarti and Srimati Chakrabarti to Ramakrishna Mission Saradapitha, Belur Math for the Construction and Development of a Cultural and Educational Center to Promote the legacy of Swamiji and Netaji”.

The chairman of Rishra Municipality, Vijay Sagar Mishra said, “It’s a matter of great joy and honor for all of us to watch the handing over ceremony of Rishra Bose House to Ramakrishna Mission Saradapitha Belur Math. Converting it to a museum will bring the common people closer to the works and activities of the great patriot Netaji Subhas Chandra Bose and Swami Vivekananda. The present generation must be made aware of the glorious history so that they can take lessons from it and go ahead in serving the motherland.”

ABOUT PMC
PMC Group, owned by Paritosh M. Chakrabarti and his family, is a US based growth oriented, diversified, global chemicals and pharmaceuticals company dedicated to innovative solutions to every need in a broad range of end markets including, plastics, consumer products, electronics, coatings, packaging, mining, personal care, food, automotive and pharmaceuticals. The Company was built on a sustainable model of growth through innovation while promoting social good. PMC operates from a global manufacturing, innovation, and marketing platform with facilities in the Americas, Europe, and Asia. More information about PMC Group and its activities around the world can be found at www.pmc-group.com.

ABOUT THE CHAKRABARTI FOUNDATION
The Chakrabarti Foundation is a non-profit organization dedicated to promoting education around the world and believes excellence in education is a primary requirement for enduring civilization. To learn more please visit https://pmc-group.com/chakrabarti-foundation.

ABOUT RAMAKRISHNA MISSION SARADAPITHA BELUR MATH
Ramakrishna Mission Saradapitha Belur Math is a well-known and reputed philanthropic organization serving the society of India and abroad irrespective of caste, color, creed, religion, nationality, gender, regional bias, etc., through its vast network of nearly more than 250 branch-centers in the fields of education, culture, religion, health, relief and rehabilitation, rural and tribal development, publications, teachings and preaching and a large number of allied areas all of which are for the all-around development of the individual and the society as a whole. More can be found at https://belurmath.org/ramakrishna-mission-saradapitha-belur.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005278/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye